Citations

Showing 10 of 108094 citations.

Metabolomics Profiling of Nephrotic Syndrome towards Biomarker Discovery
Jacob, Minnie , Nimer, Refat M. , Alabdaljabar, Mohamad S. , Sabi, Essa M. , Al‐Ansari, Mysoon M. , Housien, Maged, Sumaily, Khalid M. , Dahabiyeh, Lina A. , Rahman, Anas M. Abdel , Abdel Rahman, Anas M , Alabdaljabar, Mohamad S

Mayo Clinic

International Journal of Molecular Sciences | October 20, 2022 | Volume: 23 | Issue: 20 | Pages: 12614

10.3390/ijms232012614 | PMID 36293474 Get It

Nephrotic syndrome (NS) is a kidney illness characterized by excessive proteinuria, hypoalbuminemia, edema, and hyperlipidemia, which may lead to kidney failure and necessitate renal transplantation. End-stage renal disease, cardiovascular issues, and mortality are much more common in those with NS. Therefore, the present study aimed to identify potential new biomarkers associated with the pathogenesis and diagnosis of NS. The liquid chromatography–mass spectrometry (LC–MS) metabolomics approach was applied to profile the metabolome of human serum of patients with NS. A total of 176 metabolites were significantly altered in NS compared to the control. Arginine, proline, and tryptophan metabolism; arginine, phenylalanine, tyrosine, and tryptophan biosynthesis were the most common metabolic pathways dysregulated in NS. Furthermore, alanyl-lysine and isoleucyl-threonine had the highest discrimination between NS and healthy groups. The candidate biomarkers may lead to understanding the possible metabolic alterations associated with NS and serve as potential diagnostic biomarkers.
Measurement of wave propagation through a tube using dual transducers for elastography in arteries
Lee, Hyoung-Ki , Capron, Charles B, Liu, Hsiao‐Chuan , Roy, Tuhin , Guddati, Murthy N. , Greenleaf, James F., Urban, Matthew W. , Urban, Matthew W , Capron, Charles

Mayo Clinic

Physics in Medicine & Biology | October 20, 2022 | Volume: 67 | Issue: 22 | Pages: 225010

10.1088/1361-6560/ac9c3f | PMID 36265476 Get It

Abstract Objective. Measuring waves induced with acoustic radiation force (ARF) in arteries has been studied over the last decade. To date, it remains a challenge to quantitatively assess the local arterial biomechanical properties. The cylindrical shape and waveguide behavior of waves propagating in the arterial wall pose complexities to determining the mechanical properties of the artery. Approach . In this paper, an artery-mimicking tube in water is examined utilizing three-dimensional measurements. The cross-section of the tube is measured while a transducer is translated over 41 different positions along the length of the tube. Motion in the radial direction is calculated using two components of motion which are measured from the two orthogonal views of the cross-section. This enables more accurate estimation of motion along the circumference of tube. Main results . The results provide more information to categorize the motion in tube wall into two types of responses: a transient response and a steady state response. The transient response is caused by ARF application and the waves travel along the length of the tube for a relatively short period of time. This corresponds to the axial and circumferential propagating waves. The two circumferential waves travel along the circumference of tube in CW (clockwise) and CCW (counter-clockwise) direction and result in a standing wave. By using a directional filter, the two waves were successfully separated, and their propagation was more clearly visualized. As a steady state response, a circumferential mode is generated showing a symmetric motion (i.e. the proximal and distal walls move in the opposite direction) following the transient response. Significance. This study provides a more comprehensive understanding of the waves produced in an artery-mimicking tube with ARF application, which will provide opportunities for improving measurement of arterial mechanical properties.
Clinical Laboratory Informatics and Analytics: Challenges and Opportunities
Wheeler, Sarah , Block, Darci R , Bunch, Dustin R. , Gramz, Jamie, Leung, Edward Ki Yun , McClintock, David S. , Tuthill, J. Mark, Wheeler, Sarah E , Gramz, Jamie

Mayo Clinic

Clinical Chemistry | October 20, 2022 | Volume: 68 | Issue: 11 | Pages: 1361-1367

10.1093/clinchem/hvac157 | PMID 36264683 Get It

Cardiac computed tomography following Watchman FLX implantation: device-related thrombus or device healing?
Kramer, Anders , Korsholm, Kasper , Jensen, Jesper Møller , Nørgaard, Bjarne Linde , Peelukhana, Srikara, Herbst, Thomáš, Horton, Rodney , Kar, Saibal , Saw, Jacqueline , Alkhouli, Mohamad , Nielsen‐Kudsk, Jens Erik , Kramer, Anders Dahl , Alkhouli, Mohamad , Korsholm, Kasper , Møller Jensen, Jesper , Nørgaard, Bjarne Linde , Peelukhana, Srikara Viswanath

Mayo Clinic

European Heart Journal - Cardiovascular Imaging | October 20, 2022 | Volume: 24 | Issue: 2 | Pages: 250-259

10.1093/ehjci/jeac222 | PMID 36336848 Get It

Abstract Aims Cardiac computed tomography (CT) is increasingly utilized during follow-up after left atrial appendage closure (LAAC). Hypoattenuated thickening (HAT) is a common finding and might represent either benign device healing or device-related thrombosis (DRT). The appearance and characteristics of HAT associated with the Watchman FLX have not been previously described. Therefore, we sought to investigate cardiac CT findings during follow-up after Watchman FLX implantation with a focus on HAT and DRT. Methods and results Retrospective single-centre, observational study including all patients with successful Watchman FLX implantation and follow-up cardiac CT between March 2019 and September 2021 (n = 244). Blinded analysis of CT images was performed describing the localization, extent, and morphology of HAT and correlated to imaging and histology findings in a canine model. Relevant clinical and preclinical ethical approvals were obtained. Overall, HAT was present in 156 cases (64%) and could be classified as either subfabric hypoattenuation (n = 59), flat sessile HAT (n = 78), protruding sessile HAT (n = 16), or pedunculated HAT (n = 3). All cases of pedunculated HAT and five cases of protruding sessile HAT were considered as high-grade HAT (n = 7). Subfabric hypoattenuation and flat sessile HAT correlated with device healing and endothelialization in histological analysis of explanted devices. Conclusion Subfabric hypoattenuation and flat sessile HAT are frequent CT findings for Watchman FLX, likely representing benign device healing and endothelialization. Pedunculated HAT and protruding HAT are infrequent CT findings that might represent DRT.
Adjuvant palbociclib for ER+ breast cancer (PALLAS Trial (ABCSG-42/AFT-05/PrE0109/BIG-14-13): A preplanned analysis of the stage IIA cohort
Burstein, Harold J. , Pfeiler, Georg , Miller, Kathy, Lu, Dongrui R. , O’Brien, Patrick, Fesl, Christian , Investigators, PALLAS Trial, DeMichele, Angela , Dueck, Amylou C. , Hlauschek, Dominik , Martín, Miguel , Zdenkowski, Nicholas , Wolff, Antonio C. , Balić, Marija , Cameron, David , Balko, Justin M. , Traina, Tiffany A , Czajkowska, Dorota, Metzger, Otto , Mayer, Erica L. , Gnant, Michael , Investigators, PALLAS Trial

Mayo Clinic

Journal of Clinical Oncology | October 20, 2022 | Volume: 40 | Issue: 36_suppl | Pages: 390216-390216

10.1200/jco.2022.40.36_suppl.390216 Get It

390216 Background: CDK4/6 inhibitors have become standard of care for advanced hormone receptor positive, HER2-negative (HR+/HER2-) breast cancer in combination with endocrine therapy (ET), with one approved for high-risk patients (pts) in the adjuvant setting. The PALLAS Trial investigated the addition of palbociclib to adjuvant ET in pts with stage II-III breast cancer. Stage IIA patients were specifically enrolled to evaluate the potential benefit of using palbociclib with adjuvant ET pts diagnosed at lower risk who may have more indolent disease. Methods: In the prospective, randomized, phase III PALLAS trial, pts with HR+/HER2- early breast cancer were randomly assigned to receive adjuvant ET for at least 5 years with or without 2 years of palbociclib (125 mg orally once daily, days 1-21 of a 28-day cycle). ET was of provider’s choice. Stage IIA enrollment was capped at 1,000 patients. While the primary end point of the overall study was invasive disease-free survival (iDFS) for the entire cohort, there was a preplanned analysis of recurrence and survival endpoints in the stage IIA cohort. Outcomes were compared between arms using stratified log-rank tests and Cox models (stratification factors: chemotherapy and age ≤ 50). Results: Among 5,796 pts enrolled at 406 centers in 21 countries worldwide between 9/1/2015 and 11/30/2018, a total of 1,010 stage IIA pts were enrolled. The protocol-defined number of events occurred at a median follow-up of 50 months for this subgroup (43.1 months for the overall study). Median age within this subgroup was 54 (range 29-85 yrs), and 410 (40.6%) were pre/perimenopausal, 506 (50.1%) T2/N0 (vs T0-1/N1), 272 (26.9%) grade 3 (vs. grade1/2), and 561 (55.5%) received chemotherapy. iDFS events occurred in 31 of 503 (6.2%) pts who received palbociclib plus ET and in 45 of 507 (8.9%) pts who received ET alone, resulting in a statistically nonsignificant difference in iDFS at 4 years (92.9% vs. 92.1%; hazard ratio, 0.75; CI, 0.48 to 1.19; P = .23). Nonsignificant differences were also observed for invasive breast cancer-free, distant recurrence-free, and locoregional cancer-free survival. No significant differences in iDFS were observed in subgroups including age group, receipt of chemotherapy, tumor grade, and clinical risk (T1/N1 vs. T2/N0).Conclusions: In this preplanned analysis of the stage IIA cohort of the PALLAS trial, the addition of adjuvant palbociclib to standard ET did not improve outcomes over ET alone, suggesting no benefit from the agent in reducing the incidence of early relapse in pts with lower-stage HR+/HER2- breast cancer. Future analyses will incorporate genomic risk and other molecular patterns from the extensive transPALLAS correlative program. Additional follow-up (10-year minimum) is also underway to assess the impact of palbociclib exposure on late recurrence in HR+ disease. Clinical trial information: NCT02513394.
Combined Ophthalmic Artery and Central Retinal Vein Occlusion Secondary to Advanced Mantle Cell Lymphoma
Salman, Ali R. , Olsen, Timothy W.

Mayo Clinic

JAMA Ophthalmology | October 20, 2022 | Volume: 140 | Issue: 10 | Pages: e223230

10.1001/jamaophthalmol.2022.3230 | PMID 36264292 Get It

This case report describes a diagnosis of ophthalmic artery and central retinal vein occlusion in a female patient with a history of end-stage mantle cell lymphoma.
Acetyl-acetyl-L-leucine for Niemann-Pick type C: a multinational double-blind randomized placebo-controlled crossover study
Fields, Taylor , Billington, Ian, Churchill, Grant C. , Evans, William , Fields, Cassandra, Galione, Antony, Kay, R., Matheison, Toni, Martakis, Κyriakos , Platt, Frances M. , Factor, Mallory, Martakis, Kyriakos , Bremova-Ertl, Tatiana , Galione, Antony, Kay, Richard, Patterson, Marc C. , Factor, Mallory, Strupp, Michael Leo

Mayo Clinic

No container title available | October 20, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-2048685/v1 Get It

Abstract Background Niemann-Pick disease type C (NPC) is a rare autosomal recessive neurodegenerative lysosomal disease characterized by multiple symptoms such as progressive cerebellar ataxia and cognitive decline. The modified amino acid N-acetyl-leucine has been associated with positive symptomatic and neuroprotective, disease-modifying effects in various studies, including animal models of NPC, observational clinical case studies, and a multinational, rater-blinded Phase IIb clinical trial. Here, we describe the development of a study protocol (Sponsor Code “IB1001-301”) for the chronic treatment of symptoms in adult and pediatric patients with NPC. Methods This multinational double-blind randomized placebo-controlled crossover Phase III study will enroll patients with a genetically confirmed diagnosis of NPC patients aged 4 years and older across 16 trial sites. Patients are assessed during a baseline period and then randomized (1:1) to one of two treatment sequences: IB1001 followed by placebo or vice versa. Each sequence consists of a 12-week treatment period. The primary efficacy endpoint is based on the Scale for the Assessment and Rating of Ataxia, and secondary outcomes include cerebellar functional rating scales, clinical global impression, and quality of life assessments. Discussion Pre-clinical as well as observational and Phase IIb clinical trials have previously demonstrated that IB1001 rapidly improved symptoms, functioning, and quality of life for pediatric and adult NPC patients and is safe and well tolerated. In this placebo-controlled cross-over trial, the risk/benefit profile of IB1001 for NPC will be evaluated. It will also give information about the applicability of IB1001 as a therapeutic paradigm for other rare and common neurological disorders. Trial registrations: The trial (IB1001-301) has been registered at www.clinicaltrials.gov (NCT05163288) and www.clinicaltrialsregister.eu (EudraCT: 2021-005356-10).
Exploring Gene Expression Profiles in Primary Central Nervous System Vasculitis
Hunder, Gene G. , Ansell, Stephen M. , Parisi, Joseph E., Croci, Stefania , Brown, Robert D. , Salvarani, Carlo , Paludo, Jonas , Giannini, Caterina , Huston, John , Koster, Matthew J. , Warrington, Kenneth J.

Mayo Clinic

Annals of Neurology | October 20, 2022 | Volume: 93 | Issue: 1 | Pages: 120-130

10.1002/ana.26537 | PMID 36264136 Get It

ObjectiveThis study was undertaken to explore the gene expression profile of primary central nervous system vasculitis (PCNSV).MethodsBrain specimens of 4 patients with granulomatous vasculitis (GV), 5 with lymphocytic vasculitis (LV), 4 with amyloid β‐related angiitis (ABRA), and 4 normal controls were studied. RNA‐sequencing was performed using the Illumina Hiseq‐4,000 platform and the Illumina TruSeq Total‐RNA library. Student t test and false discovery rate tests were performed for each of the differentially expressed transcripts. Ingenuity Pathway Analysis was used for the pathway expression analysis. CIBERSORT was used to estimate the abundances of different immune cell subsets in the tissues based on gene expression data.ResultsTranscripts differentially expressed between PCNSV and normal brain indicated that endosomal, mitochondrial, and ribosome dysfunction, alterations in protein synthesis, and noncoding RNAs might be involved in PCNSV. Pathway analysis revealed the activation of dendritic cell maturation and antigen processing as well as neuroinflammation in PCNSV versus normal brain, whereas oxidative phosphorylation was inhibited. CIBERSORT estimation of immune cell subsets suggested that activated NK cells, M1 macrophages, memory B cells, and follicular helper T cells were likely to be more prevalent in PCNSV samples. Naïve CD4 T cells and monocytes were mainly estimated to be present in GV and ABRA. Plasma cell and γδ T‐cell signatures were mainly found in LV and normal brain. GV showed higher levels of genes associated with macrophage activities and T cells. ABRA showed higher levels of long noncoding RNAs and miR‐616. LV showed higher levels of genes encoding immunoglobulins.InterpretationRNA sequencing confirmed PCNSV heterogeneity. ANN NEUROL 2023;93:120–130
Alignment-free comparison of metagenomics sequences via approximate string matching
Chen, Jian , Yang, Le , Li, Lu , Goodison, Steve , Sun, Yijun

Mayo Clinic

Bioinformatics Advances | October 20, 2022 | Volume: 2 | Issue: 1 | Pages: No page available

10.1093/bioadv/vbac077 | PMID 36388153 Get It

Abstract Summary Quantifying pairwise sequence similarities is a key step in metagenomics studies. Alignment-free methods provide a computationally efficient alternative to alignment-based methods for large-scale sequence analysis. Several neural network-based methods have recently been developed for this purpose. However, existing methods do not perform well on sequences of varying lengths and are sensitive to the presence of insertions and deletions. In this article, we describe the development of a new method, referred to as AsMac that addresses the aforementioned issues. We proposed a novel neural network structure for approximate string matching for the extraction of pertinent information from biological sequences and developed an efficient gradient computation algorithm for training the constructed neural network. We performed a large-scale benchmark study using real-world data that demonstrated the effectiveness and potential utility of the proposed method. Availability and implementation The open-source software for the proposed method and trained neural-network models for some commonly used metagenomics marker genes were developed and are freely available at www.acsu.buffalo.edu/~yijunsun/lab/AsMac.html. Supplementary information Supplementary data are available at Bioinformatics online.
Current understanding of AD pathophysiology and impact of amyloid‐beta targeted treatments on biomarkers and clinical endpoints
Petersen, Ronald C. , Graf, Ana, Carrillo, María C. , Weber, Christopher J.

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | October 20, 2022 | Volume: 8 | Issue: 1 | Pages: No page available

10.1002/trc2.12361 | PMID 36284665 Get It